knowcompoundspropranolol
Specimen compound organic compoundPlate I
Propranolol

- Formula
- C16H21NO2
- Molar mass
- 259.349 g/mol
- ChEBI
- CHEBI:8499
- PubChem CID
- 4946
- InChIKey
- AQHHHDLHHXJYJD-UHFFFAOYSA-N
↑ raised 1 finding · ↓ lowered 1 finding · – no difference found
01 · the evidence, ordered
What the evidence says
- Moderate
Propranolol
36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
02 · findings
What propranolol moved, and by how much
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
- Industry funding: named on its row.
- Withdrawal due to adverse eventsMoved: raisesEvidence: ModeratePaper: PMID 390441702024
- Who
- Adults with migraine; meta-analysis of 20 randomized trials of oral propranolol versus placebo for migraine prophylaxis · n = 1,291
- Dose studied
- not reported
We found high certainty evidence that propranolol increases the proportion of patients who discontinue due to adverse events compared to placebo with a risk difference of 0.02 (95% CI 0.00 to 0.03); absolute risk difference: 20 more per 1,000 (95% CI 0 to 30).”
Quoted verbatim from European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.meta-analysisPermalink - All-cause mortalityMoved: no difference foundEvidence: ModeratePaper: PMID 282652982017
- Who
- Severely burned adults and children (TBSA >20%) in randomised trials of propranolol versus placebo or usual care; four trials reported mortality
- Dose studied
- not reported
There were no significant differences between propranolol and placebo/usual care with respect to mortality (RD −0.02 [95% CI −0.06 to 0.02]), and also, no differences were found in the sub-group analysis when assessing this outcome in children (RD −0.02 [95% CI −0.06 to 0.02]) and adults (RD −0.05 [95% CI −0.17 to 0.07]).”
Quoted verbatim from Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.meta-analysisPermalink - Diastolic blood pressureMoved: lowersEvidence: ModeratePaper: PMID 418116412026An author is affiliated with a producer
- Who
- Adults with obstructive sleep apnea (mean age 51, BMI 33.8) undergoing a 3-night CPAP withdrawal protocol; morning measurement after the night
- Dose studied
- propranolol long-acting 80 mg in the evening, versus placebo
Propranolol caused a trend in reduction of systolic morning blood pressure from 131 to 125 mm Hg (mean difference, 6.1 [−11.5, 28]) and significantly reduced diastolic blood pressure from 80 to 76 mmHg (mean difference, 4.3 [−10, 17.5]).”
Quoted verbatim from Propranolol mitigates sleep apnea-related cardiac responses during CPAP withdrawal: a randomized placebo-controlled cross-over clinical study.crossoverPermalink
No row matches these filters.
No dose is advised.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
- Industry funding: named on its row.
03 · identity
Structure
- Charge
- 0
- SMILES
- CC(C)NCC(O)COc1cccc2ccccc12
04 · figures · 1 plate
Plates

fig. 4Propranolol · MS2 [M+H]+ ESI-TOF positive · MassBank MSBNK-mFam-MC02_000986 (C. Broeckling, CC BY)
05 · the record
Sources
1,660
papers screened for propranolol
- admitted
- 3
- read and discarded
- 236
- not read yet
- 1,421
- Documented interactions
- None reported
Sources cited
3 papers · 3 findings